Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed a Form 8-K dated January 12, 2024, reporting material financing, warrant, debt, investor-rights, and compensation arrangements. The reported transactions generally closed on January 16, 2024. The filing does not present quarterly or annual operating results.
Key Financial and Capital Structure Matters
- Private placement: Celularity agreed to sell existing investor Dragasac Limited 21,410,983 shares of Class A common stock and warrants to purchase up to 5,352,746 additional shares for an aggregate purchase price of approximately $6.0 million.
- The stock and warrants were priced at $0.24898 per share and $0.125 per accompanying warrant, respectively. The warrants are immediately exercisable, carry a $0.24898 exercise price, and expire January 16, 2029.
- Warrant repricing: Existing Dragasac warrants covering 6,529,818 shares were amended and restated, reducing the exercise price from $6.77 to $0.24898 per share, subject to further adjustment provisions.
- Senior secured bridge loan: Celularity entered into a second amended and restated loan agreement with Resorts World Inc. Pte Ltd for an additional $15.0 million of principal, net of a $3.75 million original issue discount. The loan bears interest at 12.5% annually and matures July 16, 2025.
- Interest for the first year is payable in kind monthly. The filing does not state the resulting cash proceeds after the original issue discount and other transaction expenses.
- The RWI financing includes a five-year immediately exercisable warrant for up to 16,500,000 shares at $0.24898 per share and a second warrant for up to 13,500,000 shares. The second warrant is subject to stockholder approval, CFIUS clearance, and a six-month waiting period; its exercise price will equal Nasdaq’s applicable Minimum Price when exercisable.
- Proceeds are required to repay Yorkville obligations, pay certain critical vendors, fund the first settlement payment to Palantir Technologies, and support approved working capital and other uses.
Material Changes, Outlook, Risks, and Unusual Items
- The financing transactions materially increase potential share dilution through newly issued shares and warrants. The filing does not provide the fully diluted post-transaction share count.
- Celularity must use net revenues from products and services associated with its Genting Innovation distribution and manufacturing agreement to prepay the RWI loan.
- The RWI loan contains negative covenants restricting dividends, indebtedness, liens, and other activities, as well as customary events of default. Uses of proceeds outside specified categories generally require RWI approval.
- Celularity agreed to seek stockholder approvals needed for the RWI securities and any proposals required to maintain its Nasdaq listing, including a possible reverse stock split.
- Directors and executives entered into a support agreement relating to voting and transfer restrictions pending required approvals. Certain transfer restrictions extend to July 12, 2024.
- Under the Dragasac agreement, Celularity agreed to take steps to equitize 15% of executive leadership salaries. CEO Robert Hariri agreed to receive 85% of his compensation in equity, not increase his 2024 compensation, and defer cash payment of deferred compensation unless specified additional equity financing thresholds are met.
- Dragasac and RWI received information, audit, and registration rights, including potential demand registration rights for underwritten offerings.
- The company expanded the scope of an exclusive distribution and manufacturing arrangement with an affiliate of Dragasac to include several clinical, investigational, and near-term commercial cell therapy products.
- The filing provides no revenue, profit, cash-flow, margin, unrestricted cash, or liquidity runway figures and contains no formal operating guidance.
Important Facts for Investors to Verify
- Confirm the January 16, 2024 closing of both the Dragasac private placement and the RWI loan and warrant issuances.
- Review the full loan agreement for collateral, repayment mechanics, covenants, default provisions, and the impact of the $3.75 million original issue discount.
- Assess total potential dilution from the Dragasac shares, repriced warrants, RWI warrants, and any other outstanding securities.
- Monitor required Nasdaq and stockholder approvals, CFIUS clearance, and the potential reverse stock split.
- Review the company’s subsequent Form 10-K and filings for actual use of proceeds, Yorkville repayment, Palantir settlement payments, cash balances, and liquidity runway.
- Examine the amended distribution and manufacturing agreement and registration rights for their economic and control implications.